New drug cocktail shows promise for tough liver cancers
NCT ID NCT05773105
First seen Jun 14, 2026 · Last updated Jun 17, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had gotten worse despite prior therapy. The goal was to see if the combo could help control the cancer longer. Participants received both drugs and were monitored for side effects and how long the cancer stayed stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.